Biotech Archives - Page 141 of 795

2 minute read

Recursion Adds New Chemical Entity Targeting Fibrotic Diseases To Late Discovery Pipeline; Signed An Agreement With Bayer AG To In-License A New Chemical Entity That Emerged From The Companies’ Fibrosis Research Collaboration

January 4, 9:01 AM

Recursion (NASDAQ:RXRX), a leading clinical stage TechBio company decoding biology to industrialize drug discovery, today announced it has signed an agreement with Bayer AG to in-license a new chemical entity that

RXRX

2 minute read

AMA’s Reimbursement Codes For Psychedelic-Assisted Therapies Take Effect: Here’s What To Expect

By Lara Goldstein

January 3, 6:50 PM

The American Medical Association’s new coverage and reimbursement codes for FDA-legalized psychedelic-assisted therapies, the current procedural terminology (CPT) III codes, have become active for physicians and other qualified healthcare providers to apply.

CMPS

1 minute read

European Drugmaker Galapagos Collaborates With Biotech BridGene Biosciences To Develop Cancer Treatments

By Vandana Singh

January 3, 5:01 PM

On Wednesday, BridGene Biosciences Inc. announced a strategic collaboration and licensing agreement with Galapagos NV (NASDAQ: GLPG).

GLPG

1 minute read

This Analyst Downgrades Bristol-Myers Squibb, Cautions Amid Product Launch And Revenue Concerns

By Vandana Singh

January 3, 1:29 PM

BofA Securities downgraded Bristol-Myers Squibb & Co (NYSE: BMY), noting that initially, the analyst believed that Bristol's loss of exclusivity (LOEs) for drugs like Eliquis and Opdivo was widely understood and it was anticipated that new product lineup would compensate

BMY

1 minute read

Why Is Blood Disorder Focused Agios Pharmaceuticals Stock Trading Higher Today?

By Vandana Singh

January 3, 10:45 AM

Agios Pharmaceuticals Inc (NASDAQ: AGIO) says the Phase 3 ENERGIZE study of mitapivat in adults with non-transfusion-dependent (NTD) alpha- or beta-thalassemia achieved its primary

AGIO

1 minute read

Better Therapeutics And Glooko Announce Partnership To Accelerate Adoption Of AspyreRx To Treat Type 2 Diabetes In The U.S.

By Benzinga Newsdesk

January 3, 10:30 AM

-Better Therapeutics Inc., a pioneer in developing prescription digital therapeutics (PDTs) for treating cardiometabolic diseases, and Glooko, Inc., a global leader in chronic condition management, today announced a

BTTX

1 minute read

Sanara Medtech Announced That Is Has Signed An Exclusive License Agreement With Tufts University To Develop And Commercialize Patented Technology Covering 18 Unique Collagen Peptides

By Benzinga Newsdesk

January 3, 10:18 AM

As part of this agreement, Sanara has formed a new subsidiary, Sanara Collagen Peptides, LLC ("SCP"), and has issued 10% of SCP's outstanding units to Tufts. SCP has exclusive rights to develop and commercialize new

SMTI

2 minute read

Earlier Health Canada Approves Pfizer Canada’s Gene Therapy In Hemophilia B

By Benzinga Newsdesk

January 3, 10:14 AM

Pfizer Canada ULC announced that Health Canada approved BEQVEZ (fidanacogene elaparvovec), an adeno-associated viral (AAV) vector-based gene therapy for the treatment of adults (aged 18 years or older) with moderately

PFE

2 minute read

T2 Biosystems Announces FDA 510(k) Submission To Expand Use Of The FDA-Cleared T2Candida Panel To Include Pediatric Testing

By Benzinga Newsdesk

January 3, 10:01 AM

T2 Biosystems, Inc. (NASDAQ:TTOO), a leader in the rapid detection of sepsis-causing pathogens and antibiotic resistance genes, today announced that it has submitted a 510(k) premarket notification to the U.S. Food

TTOO

2 minute read

GeoVax Announces Issuance of Malaria Vaccine Patent, Patent Covers Multiple Component Vaccine For Both Prevention And Treatment

By Benzinga Newsdesk

January 3, 10:00 AM

Patent Covers Multiple Component Vaccine for Both Prevention and Treatment ATLANTA, GA, Jan. 03, 2024 (GLOBE NEWSWIRE) -- via NewMediaWire – GeoVax Labs, Inc. (NASDAQ:GOVX), a biotechnology company developing

GOVX